Abstract
One hundred and ninety-one cases of acute lymphoblastic leukaemia were entered in a trial in which, for five months, all received cytotoxic therapy with prednisolone, vincristine, mercaptopurine, L-asparaginase, and methotrexate (the latter in high dosage followed by folinic acid). Patients were then randomized to receive immunotherapy (B.C.G.), twice-weekly methotrexate, or no further treatment.
One hundred and seventy-seven patients (93%) achieved full remission and at the time of analysis, 26 months from the beginning of the trial, 143 were still alive, including 70 in their first remission. Median “post-intensive” remission lengths were 17 weeks (no treatment), 27 weeks (B.C.G.), and 52 weeks (methotrexate). The prolongation of remission by methotrexate was most evident in those patients with low initial white cell counts. B.C.G. seemed to cause lymphocytosis but was without other conspicuous effect. The incidence of toxic reactions is reported, including an unusually low rate of anaphylaxis with L-asparaginase.
These preliminary results are discussed and compared with those of similar trials.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BLOCK M., JACOBSON L. O., BETHARD W. F. Preleukemic acute human leukemia. J Am Med Assoc. 1953 Jul 11;152(11):1018–1028. doi: 10.1001/jama.1953.03690110032010. [DOI] [PubMed] [Google Scholar]
- Hryniuk W. M., Bertino J. R. Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates. J Clin Invest. 1969 Nov;48(11):2140–2155. doi: 10.1172/JCI106181. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pinkel D., Hernandez K., Borella L., Holton C., Aur R., Samoy G., Pratt C. Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer. 1971 Feb;27(2):247–256. doi: 10.1002/1097-0142(197102)27:2<247::aid-cncr2820270202>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]